Excessive fluid accumulation during stem cell mobilization: A novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients

Nelson Leung, Tessa R. Leung, Stephen S. Cha, Angela Dispenzieri, Martha Lacy, Morie Gertz

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

High-dose melphalan followed by stem cell transplantation (HDM-SCT) has become the treatment of choice for patients with immunoglobulin light chain amyloidosis (AL). Unfortunately, treatment mortality can be excessive in certain subpopulations. We have noted that patients who gained more than 2% body weight during mobilization had a poorer outcome following HDM-SCT. Excluding 2 patients for lack of weight record and denial of consent, 126 patients between July 1997 and June 2003 were retrospectively studied. Weight increased more than 2.0% during mobilization in 51.6% of the patients. Patients who accumulated more than 2.0% tended to have more proteinuria, more organs involved, lower serum albumin, more diuretic use, and dosage adjustment during mobilization. First-year mortality was significantly higher in those with more than 2% weight gain (33.9% versus 9.8%, P = .002). Multivariate analysis showed weight gain, glomerular filtration rate, and septal thickness to be independent predictors of first-year mortality. The increase in mortality was noted even after the excess weight was diuresed prior to conditioning. The impact on mortality dissipated after the first year. Weight gain during mobilization appears to be a new marker of adverse outcome following HDM-SCT. Better prognostication may improve the treatment mortality rate of these patients.

Original languageEnglish (US)
Pages (from-to)3353-3357
Number of pages5
JournalBlood
Volume106
Issue number10
DOIs
StatePublished - Nov 15 2005

Fingerprint

Hematopoietic Stem Cell Mobilization
Melphalan
Stem Cell Transplantation
Amyloidosis
Stem cells
Fluids
Survival
Mortality
Immunoglobulin Light Chains
Weight Gain
Diuretics
Serum Albumin
Weights and Measures
Glomerular Filtration Rate
Proteinuria
Therapeutics
Multivariate Analysis
Body Weight

ASJC Scopus subject areas

  • Hematology

Cite this

Excessive fluid accumulation during stem cell mobilization : A novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. / Leung, Nelson; Leung, Tessa R.; Cha, Stephen S.; Dispenzieri, Angela; Lacy, Martha; Gertz, Morie.

In: Blood, Vol. 106, No. 10, 15.11.2005, p. 3353-3357.

Research output: Contribution to journalArticle

@article{b72f23ced8574d89914750696df09d3d,
title = "Excessive fluid accumulation during stem cell mobilization: A novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients",
abstract = "High-dose melphalan followed by stem cell transplantation (HDM-SCT) has become the treatment of choice for patients with immunoglobulin light chain amyloidosis (AL). Unfortunately, treatment mortality can be excessive in certain subpopulations. We have noted that patients who gained more than 2{\%} body weight during mobilization had a poorer outcome following HDM-SCT. Excluding 2 patients for lack of weight record and denial of consent, 126 patients between July 1997 and June 2003 were retrospectively studied. Weight increased more than 2.0{\%} during mobilization in 51.6{\%} of the patients. Patients who accumulated more than 2.0{\%} tended to have more proteinuria, more organs involved, lower serum albumin, more diuretic use, and dosage adjustment during mobilization. First-year mortality was significantly higher in those with more than 2{\%} weight gain (33.9{\%} versus 9.8{\%}, P = .002). Multivariate analysis showed weight gain, glomerular filtration rate, and septal thickness to be independent predictors of first-year mortality. The increase in mortality was noted even after the excess weight was diuresed prior to conditioning. The impact on mortality dissipated after the first year. Weight gain during mobilization appears to be a new marker of adverse outcome following HDM-SCT. Better prognostication may improve the treatment mortality rate of these patients.",
author = "Nelson Leung and Leung, {Tessa R.} and Cha, {Stephen S.} and Angela Dispenzieri and Martha Lacy and Morie Gertz",
year = "2005",
month = "11",
day = "15",
doi = "10.1182/blood-2005-03-1206",
language = "English (US)",
volume = "106",
pages = "3353--3357",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Excessive fluid accumulation during stem cell mobilization

T2 - A novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients

AU - Leung, Nelson

AU - Leung, Tessa R.

AU - Cha, Stephen S.

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Gertz, Morie

PY - 2005/11/15

Y1 - 2005/11/15

N2 - High-dose melphalan followed by stem cell transplantation (HDM-SCT) has become the treatment of choice for patients with immunoglobulin light chain amyloidosis (AL). Unfortunately, treatment mortality can be excessive in certain subpopulations. We have noted that patients who gained more than 2% body weight during mobilization had a poorer outcome following HDM-SCT. Excluding 2 patients for lack of weight record and denial of consent, 126 patients between July 1997 and June 2003 were retrospectively studied. Weight increased more than 2.0% during mobilization in 51.6% of the patients. Patients who accumulated more than 2.0% tended to have more proteinuria, more organs involved, lower serum albumin, more diuretic use, and dosage adjustment during mobilization. First-year mortality was significantly higher in those with more than 2% weight gain (33.9% versus 9.8%, P = .002). Multivariate analysis showed weight gain, glomerular filtration rate, and septal thickness to be independent predictors of first-year mortality. The increase in mortality was noted even after the excess weight was diuresed prior to conditioning. The impact on mortality dissipated after the first year. Weight gain during mobilization appears to be a new marker of adverse outcome following HDM-SCT. Better prognostication may improve the treatment mortality rate of these patients.

AB - High-dose melphalan followed by stem cell transplantation (HDM-SCT) has become the treatment of choice for patients with immunoglobulin light chain amyloidosis (AL). Unfortunately, treatment mortality can be excessive in certain subpopulations. We have noted that patients who gained more than 2% body weight during mobilization had a poorer outcome following HDM-SCT. Excluding 2 patients for lack of weight record and denial of consent, 126 patients between July 1997 and June 2003 were retrospectively studied. Weight increased more than 2.0% during mobilization in 51.6% of the patients. Patients who accumulated more than 2.0% tended to have more proteinuria, more organs involved, lower serum albumin, more diuretic use, and dosage adjustment during mobilization. First-year mortality was significantly higher in those with more than 2% weight gain (33.9% versus 9.8%, P = .002). Multivariate analysis showed weight gain, glomerular filtration rate, and septal thickness to be independent predictors of first-year mortality. The increase in mortality was noted even after the excess weight was diuresed prior to conditioning. The impact on mortality dissipated after the first year. Weight gain during mobilization appears to be a new marker of adverse outcome following HDM-SCT. Better prognostication may improve the treatment mortality rate of these patients.

UR - http://www.scopus.com/inward/record.url?scp=27744488826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744488826&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-03-1206

DO - 10.1182/blood-2005-03-1206

M3 - Article

C2 - 16037390

AN - SCOPUS:27744488826

VL - 106

SP - 3353

EP - 3357

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -